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ABSTRACT 
Objective: The purpose of this study was to compare the cost-effectiveness of T2DM patients in community health centers (Pusat Kesehatan 
Masyarakat, Puskesmas) of Rancaekek, Linggar, and Nanjungmekar. 
Methods: The medicine was a combination of metformin and glimepiride; the outcome parameter was fasting glucose level, cost components were 
fee of BPJS class III and transportation cost with the patient's perspective. Pharmacoeconomic method was cost-effectiveness analysis. Respondents 
were given counseling about the importance of medicine consumption. 
Results: There were 60 respondents, which met the inclusion criteria, then grouped by gender (male (15%) and female (85%)) and age (the highest 
incidence was the range from 56 to 65 y old, 36.67%). The average cost-effectiveness ratio of Prolanis in the Puskesmas of Rancaekek, Linggar, and 
Nanjungmekar was 1,073, 956 and 1,885 IDR per decreased glucose level, respectively. The statistical analysis of decreased blood glucose was 0.341 
and the Prolanis cost was 0.399, which no difference between decreased blood glucose and Prolanis costs in the three Puskesmas. 
Conclusions: The Prolanis of Linggar Puskesmas was the most cost-effective compared to the Rancaekek and Nanjungmekar Puskesmas. 
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INTRODUCTION 
Diabetes is associated with a significant clinical and economic burden in 
the world, including Indonesia. The global projection for diabetes was 
438 million in 2025 [1]. Diabetes mellitus (DM) is a clinical syndrome 
with signs of hyperglycemia due to absolute and relative insulin 
deficiency. Deficiency of insulin, which release by pancreas β-cells, 
significantly interferes with carbohydrate, protein, and fat metabolism 
[2, 3]. Blood glucose levels are regulated by insulin as the main regulator 
of metabolic intermediaries [2]. Type 2 diabetes (T2DM), known 
as adult-onset diabetes, is characterized by high blood glucose levels, 
insulin resistance, and a relative lack of insulin [3].  
The community health center (Pusat Kesehatan Masyarakat, 
Puskesmas) is a health service facility, which organizes first-level 
public and private health efforts, with preventive and promotive 
priorities to achieve the highest degree of public health. The Health 
Social Security Administering Agency (Badan Penyelenggara 
Jaminan Sosial, BPJS) implements a Disease Management Program 
(Program Pengelolaan Penyakit Kronis, Prolanis) to control T2DM. 
The Prolanis goal is to encourage diabetes patients to achieve 
optimal quality of life at an effective and rational cost [4]. Regulation 
No. 40 of 2004 article 24 mandates Health BPJS to control of quality 
and costs, which implemented by Prolanis [5].  
The DM economic burden and its impact on a patient's life can be 
measured by economic analysis, which calculates the most cost-
effective therapeutic option [1]. Pharmacoeconomic study using the 
Cost-Effectiveness Analysis (CEA) method was conducted to control 
cost-effectiveness [6, 7]. The purpose of this study was to determine 
the decreased fasting glucose levels and the cost-effectiveness of 
T2DM patients in the Puskesmas of Rancaekek, Linggar, and 
Nanjungmekar. This study compared the implementation of Prolanis 
in three Puskesmas.  
MATERIALS AND METHODS 
Subjects  
The study was approved by the Health Research Ethics Committee of 
Dr. Hasan Sadikin Hospital, Indonesia, and was conducted accordingly 
to an approved method. The patients were undertaken for observation 
only after their informed consent. This study was a prospective 
observational study, T2DM patients were enrolled in the study for 3 
mo from May to July 2019. The population in this study was 109 
patients, but only 60 patients who willing to participating in the study. 
The sampling technique was total sampling [8]. This study compared 
the cost-effectiveness of Prolanis patients in the Rancaekek, Linggar, 
and Nanjungmekar Puskesmas, West Java, Indonesia.  
The inclusion criteria were:  
a. Patients participate in Prolanis activities and check-up routinely. 
b. Prolanis patients with T2DM. 
c. Patients receiving a combination of 500 mg metformin (three 
tablets per day) and 1 mg glimepiride (one tablet per day) [9].  
d. Patients over 18 y old. 
The exclusion criteria were:  
a. The patient was not a Prolanis participant. 
b. The patient less than 18 y old. 
c. The T2DM Prolanis participant who did not want to participate in 
the study. 
d. Patients with co-morbid conditions such as hypertension, 
hypothyroidism, dyslipidemia, coronary artery disease, and 
myocardial infarction. 
Methods 
Determination of outcome 
The outcome as an indication of medication successful was fasting 
glucose levels for 3 mo.  
Determine the cost component 
a) Determination of perspective. The perspective of this study was 
the patient's perspective. 
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b) Determination of cost components. The cost components 
were fee of BPJS class III (25,500 IDR) [10] and transportation 
cost for every month. Transportation costs were obtained from 
interviews. 
c) Pharmacoeconomic analysis. Cost-effectiveness analysis was 
evaluated in follow-up cases, which achieving glycemic control, i.e. 
fasting blood glucose<130 mg/dl [11]. The cost of health 
interventions was measured in monetary units (Indonesian Rupiah, 
IDR) and the intervention results were health indicators, both 
clinical and non-clinical (non-monetary). Data analysis was 
performed by calculating the Cost-Effectiveness Ratio (CER) with 
formula 1 and the cost-effectiveness table [12].  
CER = Cost
Effectiveness




Data were presented as the mean±standard deviation (SD). Data 
were conducted to statistical analysis using the Kolmogorov-
Smirnov test, followed by ANOVA for parametric analysis or Kruskal 
Wallis Test for non-parametric analysis.  
RESULTS AND DISCUSSION 
The Prolanis goal is to encourage participants with chronic diseases 
to achieve optimal quality of life with an indicator of 75% of 
registered participants visiting first-level health facilities having 
"good" results of specific tests for T2DM and hypertension according 
to the relevant clinical guidelines to prevent disease complications. 
The forms of Prolanis implementation include medical or 
educational consultation activities, home visit, reminder, club 
activities and health status monitoring [4]. 
The T2DM patients, which Prolanis participant at Rancaekek, 
Linggar, and Nanjungmekar Puskesmas were 49, 24, and 36 patients, 
respectively. Patients who met the inclusion criteria were 20 
patients in each Puskesmas, then filled in the informed consent and 
given counseling about the importance of medicine consumption. 
The patient distribution based on gender (table 1) showed that 
female patients (85%) higher than men (15%). This result was 
similar to the results of Alghadir et al. (2012) [13] and Awad et al. 
(2013) [14]. Female have a higher risk of developing diabetes than 
men, due to insulin resistance [15]. 
This study targeted T2DM patients ranging from 18 y old, but 
patients who came to the Puskesmas and participated in Prolanis 
were over 45 y old. This was because the Puskesmas service time 
was limited, from 8.00-12.00, but the patients have to start 
queuing at 6.00. This limitation caused there were no T2DM 
patients with productive age, i.e. 18-45 y old. The patient 
distribution based on age (table 1) showed that T2DM was mostly 
affected the 56-65 y (36.67%), followed by the 46-55 y (35.00%) 
and over 65 y (28.33%). This was due to the decreased organs 
function, thereby the increased disease risk [16]. In the world, 
diabetic patients are range from 45 to 64 y [17], with 80% of these 
patients are living in low-and middle-income countries, such as 
Indonesia [1]. The elderly people affect T2DM due to decreased 
physiology in body function and decreased insulin secretion and 
resistance, so the ability of the body's function to control blood 
glucose is less than optimal [18]. 
 
Table 1: Distribution of type 2 diabetes mellitus patients 
Variable Puskesmas 
Rancaekek Linggar Nanjungmekar 
Patients % Patients % Patients % 
Gender 
Male 3 15 4 20 2 10 
Female 17 85 16 80 18 90 
Age (years) 
<45 0 0 0 0 0 0 
46-55 3 15 8 40 10 50 
56-65 9 45 7 35 6 30 
≥ 65 8 40 5 25 4 20 
 
BPJS fee cover health services, medicines, laboratory examinations, 
and administration. All the Prolanis patients (60 people) were given 
a combination of 500 mg metformin and 1 mg glimepiride [9, 19]. 
Metformin belongs to the biguanides group, suppresses hepatic 
glucose production, increases insulin sensitivity, increases glucose 
uptake, increases fatty acid oxidation, and decreases glucose 
absorption [20]. Glimepiride belongs to sulfonylurea group, 
stimulates the release of insulin from pancreatic β-cells [21]. The 
success of T2DM treatment was assessed by a decreased fasting 
glucose level. All patients were shown decreased fasting glucose 
levels, in the range of 21-36 mg/dL, with an average of 29.65±22.86 
mg/dl (table 2). 
The decreased fasting glucose levels in the three Puskesmas were 
normal distribution with p value>0.05 indicated there was no 
significant difference between the data and the standard normal. 
This showed that the data were normally distributed and 
homogeneous, so we conducted the parametric analysis, i.e. one-way 
ANOVA. The results showed the significance value based on the 
outcome of decreased fasting sugar levels was 0.341, i.e. there was 
no significant difference. 
 
Table 2: The decreased fasting glucose levels 
Decreased fasting glucose levels (mg/dl) at the puskesmas 
Rancaekek Linggar Nanjungmekar 
32.15±26.03 21.35±17.20 35.45±22.76 
 
The average cost at Puskesmas Nanjungmekar was higher than 
other Puskesmas, with a difference of 5,750±750 and 6,350±900 
IDR (table 3). This was because of higher transportation cost, 
due to the distance between the patient's home and the 
Nanjungmekar Puskesmas was in the range of 6 to 8 km. The 
best CER was the Linggar Puskesmas (table 4). Cost analysis 
statistically assessed the overall cost in detail based on data with 
the normality test. The total cost normality test resulted in p 
value<0.05, which showed a significant difference. The data were 
not normally distributed and not homogeneous, so it is included 
in the non-parametric statistical analysis. In the non-parametric 
analysis, a Crucial Wallis test is performed. Asymptotic 
significance value of 0.339 showed there was no difference 
between the costs in the three Puskesmas. 
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Table 3: Patient cost expended 
Average costs (IDR) Patient cost expended (IDR) at the puskesmas 
Rancaekek Linggar Nanjungmekar 
BPJS fee 25,500 25,500 25,500 
Transportation 9,000±2,876 8,400±1,765 14,750±3,612 
Total 34,500±3,574 33,900±2,583 40,250±4,575 
 
Table 4: Calculation of cost-effectiveness ratios 
Prolanis at the puskesmas Average cost (IDR) Outcome (mg/dl) CER 
Rancaekek 34,500±3,574 32.15±26.03 1,073±213 
Linggar 33,900±2,583 21.35±17.20 1,587±138 
Nanjungmekar 40,250±4,575 35.45±22.76 1,173±187 
 
The cost-effectiveness table was used to determine health 
interventions relative to other health interventions [22]. The 
Prolanis in the Linggar Puskesmas was the most cost-effective 
compared to the Rancaekek and Nanjungmekar Puskesmas (table 5). 
All patients were educated that the T2DM can be maintained 
through lifestyle modification, diet control, and control of 
overweight and obesity. The community education was needed for 
diabetes control, and disease management was needed to improve 
the quality of life of T2DM patients. The data of the quality of life of 
T2DM Prolanis patients who participated in the study could not be 
processed, because they were only obedient in laboratory 
examinations and medicines. The patients were not adherent in 
education, which was observed from the attendance data on Prolanis 
activities.
 
Table 5: Alternative groups based on cost-effectiveness 
Cost-effectiveness Lower cost Same cost Higher cost 
Lower effectiveness A (need ICER calculation) B Rancaekek to Linggar 
Nanjungmekar to Linggar 
Nanjungmekar to Rancaekek 
Same effectiveness D E F 
Higher 
effectiveness 
Rancaekek to Nanjungmekar 
Linggar to Nanjungmekar 
Linggar to Rancaekek 
H I (need ICER calculation) 
 
CONCLUSION 
The Prolanis of Linggar Puskesmas was the most cost-effective 
compared to the Rancaekek and Nanjungmekar Puskesmas. 
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